ACTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company.

马萨诸塞州阿克顿，2024年6月27日（环球通讯社）--Bluejay Diagnostics，Inc.（纳斯达克代码：BJDX）（“Bluejay”或“公司”）是一家医疗技术公司，在其Symphony平台上开发快速诊断技术，以改善重症监护环境中的患者预后，今天宣布，在扣除承销折扣和公司应付的其他预计费用之前，该公司的总收益预计约为875万美元的坚定承诺包销公开发行定价。

The base offering consists of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one share of the Company’s common stock (“Common Stock”) or one pre-funded warrant to purchase one share of Common Stock (each, a “Prefunded Warrant”), two Class C warrants each to purchase one share of our common stock (each, a “Class C Warrant”) and one Class D Warrant to purchase such number of shares of common stock as determined in the Class D Warrant (each, a “Class D Warrant” and together with the Class C Warrants, the “Common Warrants”).

基本发售包括5368098份普通股或预缴股款单位，每个单位由一股公司普通股（“普通股”）或一份购买一股普通股的预缴认股权证（各称为“预缴认股权证”）、两份购买一股我们普通股的C类认股权证（各称为“C类认股权证”）和一份购买D类认股权证（各称为“D类认股权证”，与C类认股权证一起称为“普通认股权证”）中确定数量的普通股的D类认股权证组成。

The purchase price of each Common Unit was $1.63, and the purchase price of each Prefunded Unit is $1.6299 (which is equal to the public offering price per Common Unit minus $0.0001). The Prefunded Warrants will be immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full..

每个普通股的购买价格为1.63美元，每个预支股的购买价格为1.6299美元（等于每个普通股的公开发行价格减去0.0001美元）。预缴认股权证将立即行权，并可随时行权，直至所有预缴认股权证全部行权。。

The Class C Warrants, which will not be exercisable until approval by the Company’s stockholders, will have an initial exercise price of $1.96 per share, and will expire five (5) years from the date of such stockholder approval. Each Class D Warrant will be exercisable immediately. The exercise price and number of shares of Common Stock issuable under the Class D Warrants are subject to adjustment as described in the Class D Warrant.

C类认股权证的初始行权价格为每股1.96美元，在获得公司股东批准之前不得行权，自股东批准之日起五（5）年内到期。每个D类认股权证将立即行使。D类认股权证下可发行普通股的行权价格和股数可根据D类认股权证的规定进行调整。

The Company intends to use the net proceeds from the offering to (i) repay $2.3 million in outstanding debt that will be due and payable upon consummation of the offering and (ii) fund matters related to obtaining FDA approval (including clinical studies related thereto), as well as for other research and development activities, and for general working capital needs..

公司打算将此次发售的净收益用于（i）偿还230万美元的未偿债务，这些债务将在发售完成后到期应付，以及（ii）与获得FDA批准（包括与之相关的临床研究）相关的资金事宜，以及其他研究和开发活动，以及一般营运资金需求。。

In addition, the Company has granted Aegis Capital Corp. a 45-day option to purchase additional shares of Common Stock and/or Common Warrants, representing up to 15% of the number of securities sold in the offering, solely to cover over-allotments, if any.

此外，该公司已授予Aegis Capital Corp.45天的期权，以购买普通股和/或普通认股权证的额外股份，占发行中出售证券数量的15%，仅用于支付超额配售（如果有的话）。

The closing of the offering is expected to occur on June 28, 2024, subject to the satisfaction of customary closing conditions.

预计本次发行将于2024年6月28日结束，但须满足常规交割条件。

Aegis Capital Corp. acted as the underwriter for the offering. Hogan Lovells US LLP acted as counsel to the Company for the offering. Kaufman & Canoles, P.C. served as counsel to Aegis Capital Corp. for the offering.

Aegis Capital Corp.担任本次发行的承销商。Hogan Lovells US LLP担任本次发行的法律顾问。Kaufman&Canoles，P.C.担任Aegis Capital Corp.的法律顾问。

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-280253) originally filed with the Securities and Exchange Commission (“SEC”) on June 17, 2024, as amended, and which registration statement became effective on June 26, 2024. The offering is being made only by means of a prospectus, which forms a part of the effective registration statement.

上述证券是根据最初于2024年6月17日提交给证券交易委员会（“SEC”）的表S-1（文件号333-280253）登记声明（经修订）提供的，该登记声明于2024年6月26日生效。此次发售仅通过招股说明书进行，招股说明书是有效注册声明的一部分。

When available, electronic copies of the final prospectus may be obtained for free on the SEC's website located at http://www.sec.gov and may also be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010.

如果可用，可在SEC网站上免费获得最终招股说明书的电子副本，网址为http://www.sec.gov也可以联系Aegis Capital Corp.，联系地址：Syndicate Department，1345 Avenue of the Americas，27th floor，New York，NY 10105syndicate@aegiscap.com，或致电（212）813-1010。

Before investing in this offering, interested parties should read in their entirety the registration statement and the preliminary prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such registration statement and the preliminary prospectus, which provide more information about the Company and the offering..

在投资本次发行之前，利益相关方应完整阅读登记声明和初步招股说明书以及公司向SEC提交的其他文件，这些文件通过引用纳入登记声明和初步招股说明书中，这些文件提供了有关公司和本次发行的更多信息。。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售或招揽购买这些证券的要约，也不构成在根据任何州或其他司法管辖区的证券法注册或取得资格之前，在任何州或其他司法管辖区出售这些证券都是非法的。。

About Bluejay Diagnostics:

关于Bluejay Diagnostics：

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions.

Bluejay Diagnostics，Inc.是一家医疗诊断公司，专注于使用Symphony系统改善患者预后，Symphony系统是一种经济高效，快速，接近患者的测试系统，用于败血症分类和疾病进展监测。Bluejay的第一个候选产品是败血症的IL-6测试，旨在从“样本到结果”大约20分钟内提供准确可靠的结果，以帮助医疗专业人员做出更早更好的分类/治疗决策。

More information is available at www.bluejaydx.com..

有关更多信息，请访问www.bluejaydx.com。。

Forward-Looking Statements:

前瞻性声明：

This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements in this press release include, without limitation, statements pertaining to the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds from the offering.

本新闻稿包含公司认为符合《私人诉讼改革法案》含义的“前瞻性声明”的声明。本新闻稿中的前瞻性声明包括但不限于有关完成招股、满足与招股相关的惯例交割条件以及招股收益的预期用途的声明。

Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest”, “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes.

前瞻性陈述可以用“预期”，“相信”，“估计”，“期望”，“打算”，“可能”，“计划”，“项目”，“寻求”，“应该”，“建议”，“意志”和类似的表达来识别。本公司已将这些前瞻性陈述基于其当前对未来事件的预期和预测，然而，实际结果或事件可能与本公司所作前瞻性陈述中披露或暗示的计划、意图和预期存在重大差异。

These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q.

这些声明只是预测，涉及已知和未知的风险、不确定性和其他因素，包括市场和其他条件以及第1A项下讨论的因素。我们最近向证券交易委员会提交的10-K表格中的“风险因素”，该表格由公司随后的10-Q表格季度报告更新。

You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release.

您不应过度依赖这些前瞻性陈述，因为它们存在风险和不确定性，未来期间的实际结果和表现可能不会发生，也可能与本新闻稿中前瞻性陈述所建议的任何未来结果或表现有实质性差异。

This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future event.

本新闻稿截至上述日期。公司没有义务更新任何前瞻性声明，无论是由于新信息、未来事件。

Investor Contact:

投资者联系人：

Neil Dey

Neil Dey

Bluejay Diagnostics, Inc.

Bluejay诊断公司。

neil.dey@bluejaydx.com

neil.dey@bluejaydx.com

978-631-0310

978-631-0310

Website: www.bluejaydx.com

网址：www.bluejaydx.com